Propofol spray - Manhattan Pharmaceuticals/NovaDel Pharma

Drug Profile

Propofol spray - Manhattan Pharmaceuticals/NovaDel Pharma

Alternative Names: Propofol lingual spray; Propofol LS

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Manhattan Pharmaceuticals; NovaDel Pharma
  • Developer Manhattan Pharmaceuticals
  • Class General anaesthetics; Phenols; Small molecules
  • Mechanism of Action GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Sedation

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Aug 2009 Propofol spray is still available for licensing (http://www.manhattanpharma.com)
  • 11 Feb 2008 Propofol spray is available for licensing (http://manhattanpharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top